Sidley Represents Shinobi Therapeutics in its Series A Financing

Sidley represented Shinobi Therapeutics, a biotechnology company developing a new class of immune-evasive iPS-T cell therapies, in its US$51 million Series A financing. The round was led by EQT Life Sciences, F-Prime Capital, and Eight Roads Ventures Japan, with participation from Astellas Venture Management, Fast Track Initiative, JIC Venture Growth Investments, and D3 LLC.

Additional information about the transaction can be found here. 

The Sidley team was led by partners Asher Rubin (Technology and Life Sciences Transactions) 
and Alison Lehner (Emerging Companies and Venture Capital) with support from Shaika Ahmed and Yahel Kaplan (Emerging Companies and Venture Capital), as well as Idan Netser and Alvin Wang (Tax).